APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PD-1 and PD-L1 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global PD-1 and PD-L1 Inhibitor Market Outlook and Growth Opportunities 2026

Report ID 174022710430 December 2025193 pages

Choose your research edition.

Industry ResearchPD-1 and PD-L1 Inhibitor Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1 and PD-L1 Inhibitor Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal PD-1 and PD-L1 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1 and PD-L1 Inhibitor Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1 and PD-L1 Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global PD-1 and PD-L1 Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the PD-1 and PD-L1 Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the PD-1 and PD-L1 Inhibitor market include Bristol Myers Squibb, Bristol-Myers Squibb, Regeneron Pharmaceuticals, AstraZeneca, Beigene, Hengrui Medicine, Pfizer, Junshi Biosciences and Akeso, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PD-1 and PD-L1 Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PD-1 and PD-L1 Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-1 and PD-L1 Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PD-1 and PD-L1 Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

PD-1 and PD-L1 Inhibitor Segment by Company

Bristol Myers Squibb

Bristol-Myers Squibb

Regeneron Pharmaceuticals

AstraZeneca

Beigene

Hengrui Medicine

Pfizer

Junshi Biosciences

Akeso

Alphamab Oncology

Roche

Merck

Sanofi

Innovent Biologics

PD-1 and PD-L1 Inhibitor Segment by Type

Monoclonal Antibody

Bispecific Antibody

PD-1 and PD-L1 Inhibitor Segment by Application

Lung Cancer

Breast Cancer

Stomach Cancer

Rectal Cancer

Others

PD-1 and PD-L1 Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global PD-1 and PD-L1 Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions PD-1 and PD-L1 Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PD-1 and PD-L1 Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze PD-1 and PD-L1 Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PD-1 and PD-L1 Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PD-1 and PD-L1 Inhibitor industry.

Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of PD-1 and PD-L1 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of PD-1 and PD-L1 Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PD-1 and PD-L1 Inhibitor Industry Trends Table 2. PD-1 and PD-L1 Inhibitor Industry Drivers Table 3. PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges Table 4. PD-1 and PD-L1 Inhibitor Industry Restraints Table 5. Global PD-1 and PD-L1 Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PD-1 and PD-L1 Inhibitor Revenue Share by Company (2021-2026) Table 7. Global PD-1 and PD-L1 Inhibitor Sales Volume by Company (Tons) & (2021-2026) Table 8. Global PD-1 and PD-L1 Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global PD-1 and PD-L1 Inhibitor Average Price (US$/Ton) of Company (2021-2026) Table 10. Global PD-1 and PD-L1 Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global PD-1 and PD-L1 Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global PD-1 and PD-L1 Inhibitor Company, Product Type & Application Table 13. Global PD-1 and PD-L1 Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global PD-1 and PD-L1 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Monoclonal Antibody Table 18. Significant Companies of Bispecific Antibody Table 19. Global PD-1 and PD-L1 Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global PD-1 and PD-L1 Inhibitor Sales Volume by Type (2021-2026) & (Tons) Table 21. Global PD-1 and PD-L1 Inhibitor Sales Volume by Type (2027-2032) & (Tons) Table 22. Global PD-1 and PD-L1 Inhibitor Sales Volume Share by Type (2021-2026) Table 23. Global PD-1 and PD-L1 Inhibitor Sales Volume Share by Type (2027-2032) Table 24. Global PD-1 and PD-L1 Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global PD-1 and PD-L1 Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global PD-1 and PD-L1 Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global PD-1 and PD-L1 Inhibitor Sales Value Share by Type (2021-2026) Table 28. Global PD-1 and PD-L1 Inhibitor Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Lung Cancer Table 30. Significant Companies of Breast Cancer Table 31. Significant Companies of Stomach Cancer Table 32. Significant Companies of Rectal Cancer Table 33. Significant Companies of Others Table 34. Global PD-1 and PD-L1 Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 35. Global PD-1 and PD-L1 Inhibitor Sales Volume by Application (2021-2026) & (Tons) Table 36. Global PD-1 and PD-L1 Inhibitor Sales Volume by Application (2027-2032) & (Tons) Table 37. Global PD-1 and PD-L1 Inhibitor Sales Volume Share by Application (2021-2026) Table 38. Global PD-1 and PD-L1 Inhibitor Sales Volume Share by Application (2027-2032) Table 39. Global PD-1 and PD-L1 Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global PD-1 and PD-L1 Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global PD-1 and PD-L1 Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global PD-1 and PD-L1 Inhibitor Sales Value Share by Application (2021-2026) Table 43. Global PD-1 and PD-L1 Inhibitor Sales Value Share by Application (2027-2032) Table 44. Global PD-1 and PD-L1 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 45. Global PD-1 and PD-L1 Inhibitor Sales by Region (2021-2026) & (Tons) Table 46. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2021-2026) Table 47. Global PD-1 and PD-L1 Inhibitor Sales by Region (2027-2032) & (Tons) Table 48. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2027-2032) Table 49. Global PD-1 and PD-L1 Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global PD-1 and PD-L1 Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global PD-1 and PD-L1 Inhibitor Sales Value Share by Region (2021-2026) Table 52. Global PD-1 and PD-L1 Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global PD-1 and PD-L1 Inhibitor Sales Value Share by Region (2027-2032) Table 54. Global PD-1 and PD-L1 Inhibitor Market Average Price (US$/Ton) by Region (2021-2026) Table 55. Global PD-1 and PD-L1 Inhibitor Market Average Price (US$/Ton) by Region (2027-2032) Table 56. Global PD-1 and PD-L1 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 57. Global PD-1 and PD-L1 Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 59. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2026) Table 60. Global PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 61. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2027-2032) Table 62. Global PD-1 and PD-L1 Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global PD-1 and PD-L1 Inhibitor Sales Value Market Share by Country (2021-2026) Table 64. Global PD-1 and PD-L1 Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global PD-1 and PD-L1 Inhibitor Sales Value Market Share by Country (2027-2032) Table 66. Bristol Myers Squibb Company Information Table 67. Bristol Myers Squibb Business Overview Table 68. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 69. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio Table 70. Bristol Myers Squibb Recent Development Table 71. Bristol-Myers Squibb Company Information Table 72. Bristol-Myers Squibb Business Overview Table 73. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 74. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio Table 75. Bristol-Myers Squibb Recent Development Table 76. Regeneron Pharmaceuticals Company Information Table 77. Regeneron Pharmaceuticals Business Overview Table 78. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 79. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio Table 80. Regeneron Pharmaceuticals Recent Development Table 81. AstraZeneca Company Information Table 82. AstraZeneca Business Overview Table 83. AstraZeneca PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 84. AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio Table 85. AstraZeneca Recent Development Table 86. Beigene Company Information Table 87. Beigene Business Overview Table 88. Beigene PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 89. Beigene PD-1 and PD-L1 Inhibitor Product Portfolio Table 90. Beigene Recent Development Table 91. Hengrui Medicine Company Information Table 92. Hengrui Medicine Business Overview Table 93. Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 94. Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio Table 95. Hengrui Medicine Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 99. Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio Table 100. Pfizer Recent Development Table 101. Junshi Biosciences Company Information Table 102. Junshi Biosciences Business Overview Table 103. Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 104. Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio Table 105. Junshi Biosciences Recent Development Table 106. Akeso Company Information Table 107. Akeso Business Overview Table 108. Akeso PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 109. Akeso PD-1 and PD-L1 Inhibitor Product Portfolio Table 110. Akeso Recent Development Table 111. Alphamab Oncology Company Information Table 112. Alphamab Oncology Business Overview Table 113. Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 114. Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio Table 115. Alphamab Oncology Recent Development Table 116. Roche Company Information Table 117. Roche Business Overview Table 118. Roche PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 119. Roche PD-1 and PD-L1 Inhibitor Product Portfolio Table 120. Roche Recent Development Table 121. Merck Company Information Table 122. Merck Business Overview Table 123. Merck PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 124. Merck PD-1 and PD-L1 Inhibitor Product Portfolio Table 125. Merck Recent Development Table 126. Sanofi Company Information Table 127. Sanofi Business Overview Table 128. Sanofi PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 129. Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio Table 130. Sanofi Recent Development Table 131. Innovent Biologics Company Information Table 132. Innovent Biologics Business Overview Table 133. Innovent Biologics PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 134. Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio Table 135. Innovent Biologics Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. PD-1 and PD-L1 Inhibitor Distributors List Table 139. PD-1 and PD-L1 Inhibitor Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. PD-1 and PD-L1 Inhibitor Product Image Figure 2. Global PD-1 and PD-L1 Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1 and PD-L1 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global PD-1 and PD-L1 Inhibitor Sales (2021-2032) & (Tons) Figure 5. Global PD-1 and PD-L1 Inhibitor Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global PD-1 and PD-L1 Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Monoclonal Antibody Image Figure 10. Bispecific Antibody Image Figure 11. Global PD-1 and PD-L1 Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global PD-1 and PD-L1 Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global PD-1 and PD-L1 Inhibitor Sales Volume Share by Type (2021-2032) Figure 14. Global PD-1 and PD-L1 Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global PD-1 and PD-L1 Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global PD-1 and PD-L1 Inhibitor Sales Value Share by Type (2021-2032) Figure 17. Lung Cancer Image Figure 18. Breast Cancer Image Figure 19. Stomach Cancer Image Figure 20. Rectal Cancer Image Figure 21. Others Image Figure 22. Global PD-1 and PD-L1 Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 23. Global PD-1 and PD-L1 Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global PD-1 and PD-L1 Inhibitor Sales Volume Share by Application (2021-2032) Figure 25. Global PD-1 and PD-L1 Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global PD-1 and PD-L1 Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global PD-1 and PD-L1 Inhibitor Sales Value Share by Application (2021-2032) Figure 28. Global PD-1 and PD-L1 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 29. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global PD-1 and PD-L1 Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global PD-1 and PD-L1 Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America PD-1 and PD-L1 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 33. North America PD-1 and PD-L1 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe PD-1 and PD-L1 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 35. Europe PD-1 and PD-L1 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America PD-1 and PD-L1 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 39. South America PD-1 and PD-L1 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa PD-1 and PD-L1 Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa PD-1 and PD-L1 Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. PD-1 and PD-L1 Inhibitor Value Chain Figure 127. Manufacturing Cost Structure Figure 128. PD-1 and PD-L1 Inhibitor Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • Bispecific Antibody
Applications
  • Lung Cancer
  • Breast Cancer
  • Stomach Cancer
  • Rectal Cancer
  • Others
Companies covered
  • Bristol Myers Squibb
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals
  • AstraZeneca
  • Beigene
  • Hengrui Medicine
  • Pfizer
  • Junshi Biosciences
  • Akeso
  • Alphamab Oncology
  • Roche
  • Merck
  • Sanofi
  • Innovent Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PD-1 and PD-L1 Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global PD-1 and PD-L1 Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global PD-1 and PD-L1 Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 PD-1 and PD-L1 Inhibitor Market Dynamics
  1. 2.1 PD-1 and PD-L1 Inhibitor Industry Trends
  2. 2.2 PD-1 and PD-L1 Inhibitor Industry Drivers
  3. 2.3 PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges
  4. 2.4 PD-1 and PD-L1 Inhibitor Industry Restraints
3 PD-1 and PD-L1 Inhibitor Market by Company
  1. 3.1 Global PD-1 and PD-L1 Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global PD-1 and PD-L1 Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global PD-1 and PD-L1 Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global PD-1 and PD-L1 Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global PD-1 and PD-L1 Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global PD-1 and PD-L1 Inhibitor Company Product Type and Application
  8. 3.8 Global PD-1 and PD-L1 Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global PD-1 and PD-L1 Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 PD-1 and PD-L1 Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 PD-1 and PD-L1 Inhibitor Market by Type
  1. 4.1 PD-1 and PD-L1 Inhibitor Type Introduction
  2. 4.1.1 Monoclonal Antibody
  3. 4.1.2 Bispecific Antibody
  4. 4.2 Global PD-1 and PD-L1 Inhibitor Sales Volume by Type
  5. 4.2.1 Global PD-1 and PD-L1 Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global PD-1 and PD-L1 Inhibitor Sales Volume by Type (2021-2032)
  7. 4.2.3 Global PD-1 and PD-L1 Inhibitor Sales Volume Share by Type (2021-2032)
  8. 4.3 Global PD-1 and PD-L1 Inhibitor Sales Value by Type
  9. 4.3.1 Global PD-1 and PD-L1 Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global PD-1 and PD-L1 Inhibitor Sales Value by Type (2021-2032)
  11. 4.3.3 Global PD-1 and PD-L1 Inhibitor Sales Value Share by Type (2021-2032)
5 PD-1 and PD-L1 Inhibitor Market by Application
  1. 5.1 PD-1 and PD-L1 Inhibitor Application Introduction
  2. 5.1.1 Lung Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Stomach Cancer
  5. 5.1.4 Rectal Cancer
  6. 5.1.5 Others
  7. 5.2 Global PD-1 and PD-L1 Inhibitor Sales Volume by Application
  8. 5.2.1 Global PD-1 and PD-L1 Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global PD-1 and PD-L1 Inhibitor Sales Volume by Application (2021-2032)
  10. 5.2.3 Global PD-1 and PD-L1 Inhibitor Sales Volume Share by Application (2021-2032)
  11. 5.3 Global PD-1 and PD-L1 Inhibitor Sales Value by Application
  12. 5.3.1 Global PD-1 and PD-L1 Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global PD-1 and PD-L1 Inhibitor Sales Value by Application (2021-2032)
  14. 5.3.3 Global PD-1 and PD-L1 Inhibitor Sales Value Share by Application (2021-2032)
6 PD-1 and PD-L1 Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PD-1 and PD-L1 Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global PD-1 and PD-L1 Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global PD-1 and PD-L1 Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global PD-1 and PD-L1 Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global PD-1 and PD-L1 Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global PD-1 and PD-L1 Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global PD-1 and PD-L1 Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America PD-1 and PD-L1 Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America PD-1 and PD-L1 Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe PD-1 and PD-L1 Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe PD-1 and PD-L1 Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America PD-1 and PD-L1 Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America PD-1 and PD-L1 Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa PD-1 and PD-L1 Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa PD-1 and PD-L1 Inhibitor Sales Value Share by Country, 2025 VS 2032
7 PD-1 and PD-L1 Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global PD-1 and PD-L1 Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PD-1 and PD-L1 Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global PD-1 and PD-L1 Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global PD-1 and PD-L1 Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global PD-1 and PD-L1 Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global PD-1 and PD-L1 Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt PD-1 and PD-L1 Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt PD-1 and PD-L1 Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt PD-1 and PD-L1 Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol Myers Squibb
  2. 8.1.1 Bristol Myers Squibb Company Information
  3. 8.1.2 Bristol Myers Squibb Business Overview
  4. 8.1.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
  6. 8.1.5 Bristol Myers Squibb Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Regeneron Pharmaceuticals
  14. 8.3.1 Regeneron Pharmaceuticals Company Information
  15. 8.3.2 Regeneron Pharmaceuticals Business Overview
  16. 8.3.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio
  18. 8.3.5 Regeneron Pharmaceuticals Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Beigene
  26. 8.5.1 Beigene Company Information
  27. 8.5.2 Beigene Business Overview
  28. 8.5.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Beigene PD-1 and PD-L1 Inhibitor Product Portfolio
  30. 8.5.5 Beigene Recent Developments
  31. 8.6 Hengrui Medicine
  32. 8.6.1 Hengrui Medicine Company Information
  33. 8.6.2 Hengrui Medicine Business Overview
  34. 8.6.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio
  36. 8.6.5 Hengrui Medicine Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Junshi Biosciences
  44. 8.8.1 Junshi Biosciences Company Information
  45. 8.8.2 Junshi Biosciences Business Overview
  46. 8.8.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio
  48. 8.8.5 Junshi Biosciences Recent Developments
  49. 8.9 Akeso
  50. 8.9.1 Akeso Company Information
  51. 8.9.2 Akeso Business Overview
  52. 8.9.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Akeso PD-1 and PD-L1 Inhibitor Product Portfolio
  54. 8.9.5 Akeso Recent Developments
  55. 8.10 Alphamab Oncology
  56. 8.10.1 Alphamab Oncology Company Information
  57. 8.10.2 Alphamab Oncology Business Overview
  58. 8.10.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio
  60. 8.10.5 Alphamab Oncology Recent Developments
  61. 8.11 Roche
  62. 8.11.1 Roche Company Information
  63. 8.11.2 Roche Business Overview
  64. 8.11.3 Roche PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Roche PD-1 and PD-L1 Inhibitor Product Portfolio
  66. 8.11.5 Roche Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Merck PD-1 and PD-L1 Inhibitor Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
  79. 8.14 Innovent Biologics
  80. 8.14.1 Innovent Biologics Company Information
  81. 8.14.2 Innovent Biologics Business Overview
  82. 8.14.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio
  84. 8.14.5 Innovent Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PD-1 and PD-L1 Inhibitor Value Chain Analysis
  2. 9.1.1 PD-1 and PD-L1 Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PD-1 and PD-L1 Inhibitor Sales Mode & Process
  6. 9.2 PD-1 and PD-L1 Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PD-1 and PD-L1 Inhibitor Distributors
  9. 9.2.3 PD-1 and PD-L1 Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst